Malignant neoplasm of peritoneum, unspecified
ICD-10 C48.2 is a billable code used to indicate a diagnosis of malignant neoplasm of peritoneum, unspecified.
C48.2 refers to malignant neoplasms located in the peritoneum, which is the serous membrane lining the abdominal cavity and covering the abdominal organs. These tumors can arise from various cell types, including mesothelial cells, and may present as primary peritoneal carcinomas or secondary tumors resulting from metastasis. The peritoneum is a common site for the spread of cancers originating in other organs, such as ovarian, colorectal, and gastric cancers. Symptoms may include abdominal pain, ascites, and changes in bowel habits. Diagnosis typically involves imaging studies, such as CT scans or MRIs, and may be confirmed through biopsy. Treatment often requires a multidisciplinary approach, including surgical intervention, chemotherapy, and palliative care, depending on the tumor's origin, stage, and overall patient health. Grading of the tumor is essential for determining prognosis and treatment strategies, with higher-grade tumors generally associated with poorer outcomes. Accurate coding is crucial for appropriate reimbursement and tracking of cancer incidence and treatment outcomes.
Detailed pathology reports, imaging studies, and treatment plans must be documented.
Management of patients with peritoneal carcinomatosis, treatment planning for chemotherapy, and surgical interventions.
Ensure accurate staging and grading are documented to support coding and treatment decisions.
Operative reports detailing the extent of disease and surgical findings.
Surgical resection of peritoneal tumors, management of complications such as bowel obstruction.
Document the rationale for surgical intervention and any findings that may affect coding.
Used when a malignant neoplasm of the peritoneum is suspected and requires surgical exploration.
Operative report detailing findings and any biopsies taken.
Surgeons must document the extent of disease and any complications encountered.
Grading helps determine the aggressiveness of the tumor and guides treatment decisions. Higher-grade tumors typically require more aggressive treatment and have a poorer prognosis.
